Radiolabeled biologics whether amino acids, cells, antibodies, proteins, viruses or synthetic ligands have potential for functional imaging and therapy. To ...

Neuraly and Enigma Biomedical have signed an agreement for PMI04, a positron emission tomography (PET) imaging biomarker ... such as Parkinson's disease, multiple sclerosis, and Alzheimer's ...

NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies for neurodegenerative diseases, announced it has received approval for its Phase 2 clinical trial from the European ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. [Operator instructions] Today's conference is being recorded. Thank you. I ...

Widespread neurological conditions, including Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis ... resonance imaging (MRI), positron emission tomography (PET), and ...

For 12 patients (27 %) the PET imaging and blood sampling were obtained on the ... and at ECTRIMS 2022, Amsterdam, Holland (Multiple Sclerosis Journal, 2022; 28(3):suppl).

hsr.it Objective To investigate monoaminergic network abnormalities in patients with multiple sclerosis (MS ... emission tomography (PET)-based constrained independent component analysis (ICA) on ...

At this time, I'd like to welcome everyone to the Biogen fourth-quarter and full-year 2024 earnings call and business update. (Operator Instructions) Today's conference is being recorded. Thank you. I ...

and multiple sclerosis. Enigma plans to focus its development efforts on utilizing PMI04 for the assessment of neurodegenerative diseases. Currently, PET imaging targeting TSPO (Translocator Protein) ...

in all four limbs of the patients with PM/DM as well as in 22 patients with amyotrophic lateral sclerosis (ALS) with similar disabilities. In 24 patients with PM/DM, MRI and FDG PET findings were ...